These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29997042)

  • 1. Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits.
    Fahmy HM; Saad EAES; Sabra NM; El-Gohary AA; Mohamed FF; Gaber MH
    Int J Pharm; 2018 Sep; 548(1):597-608. PubMed ID: 29997042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
    Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
    Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.
    Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
    PLoS One; 2011; 6(9):e24513. PubMed ID: 21931735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits.
    Shafaa MW; Sabra NM; Fouad RA
    Biopharm Drug Dispos; 2011 Dec; 32(9):507-17. PubMed ID: 22028305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
    PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents.
    Brugnera M; Vicario-de-la-Torre M; González-Cela Casamayor MA; López-Cano JJ; Bravo-Osuna I; Huete-Toral F; González Rubio ML; Carracedo G; Molina-Martínez IT; Andrés-Guerrero V; Herrero-Vanrell R
    Drug Deliv Transl Res; 2024 Oct; 14(10):2804-2822. PubMed ID: 38602615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits.
    Jessen BA; Shiue MH; Kaur H; Miller P; Leedle R; Guo H; Evans M
    J Ocul Pharmacol Ther; 2013; 29(6):574-85. PubMed ID: 23489175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma.
    Kashiwagi K; Ito K; Haniuda H; Ohtsubo S; Takeoka S
    Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5629-37. PubMed ID: 23868986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results.
    Giarmoukakis A; Labiris G; Sideroudi H; Tsimali Z; Koutsospyrou N; Avgoustakis K; Kozobolis V
    Exp Eye Res; 2013 Jul; 112():29-36. PubMed ID: 23603320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication.
    Hathout RM; Gad HA; Abdel-Hafez SM; Nasser N; Khalil N; Ateyya T; Amr A; Yasser N; Nasr S; Metwally AA
    Int J Pharm; 2019 Feb; 556():192-199. PubMed ID: 30553005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo.
    Zhang HH; Luo QH; Yang ZJ; Pan WS; Nie SF
    Drug Deliv; 2011; 18(7):502-10. PubMed ID: 21790329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of substituting latanoprost 0.005% for unoprostone 0.12%].
    Otori Y; Tokugawa H; Morimura H; Okada M; Goto H; Miki A; Tano Y
    Nippon Ganka Gakkai Zasshi; 2004 Apr; 108(4):207-12. PubMed ID: 15148736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.
    Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R
    Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro study of the cytotoxicity of thymoquinone/curcumin fluorescent liposomes.
    Fahmy HM
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Nov; 392(11):1465-1476. PubMed ID: 31377882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.